Protectimmun partners with J&J, Imperial College

Wednesday, September 30, 2015

Protectimmun, a Germany-based biopharmaceutical R&D company, has entered into a research funding agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Imperial College London. The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research conducted at Imperial College by professor Clare Lloyd with one of Protectimmun’s lead candidates in a proof-of-concept disease model of allergic asthma developed by Lloyd.

[Read More]